Neurocrine Biosciences reported 83.17 in PE Price to Earnings for its fiscal quarter ending in September of 2026.





Pe Change Date
AbbVie 23.45 0.51 Sep/2026
Acadia Pharmaceuticals 9.52 1.81 Sep/2026
Agios Pharmaceuticals 3.56 0 Mar/2026
ALKERMES 262.4 126.59 Sep/2026
Alnylam Pharmaceuticals 13.17 62.47 Sep/2026
Amgen 18.6 0.53 Sep/2026
Biogen 29.15 5.92 Sep/2026
BioMarin Pharmaceutical 53.62 32.55 Sep/2026
Exelixis 18.43 0.41 Sep/2026
Gilead Sciences 17.68 4.18 Sep/2026
Halozyme Therapeutics 16.12 3.61 Sep/2026
Incyte 54.54 40.08 Sep/2026
Ionis Pharmaceuticals 396.15 79.28 Sep/2022
Neurocrine Biosciences 83.17 61.07 Sep/2026
Pfizer 15.2 3.72 Sep/2026
Prothena 22.11 11.37 Mar/2022
Regeneron Pharmaceuticals 15.46 9.68 Jun/2026
Repligen 138.54 33.44 Sep/2026
Rigel Pharmaceuticals 8.61 8.4 Mar/2025
Sarepta Therapeutics 32.09 22.66 Sep/2026
Teva Pharmaceutical Industries 18.7 5.9 Sep/2026
Vertex Pharmaceuticals 29.35 1.3 Sep/2026